Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.78 |
| ▸ | F2 | P00734 | 3/20 | 0.50 |
| ▸ | PLG | P00747 | 3/20 | 0.50 |
| ▸ | PROC | P04070 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619613 | 0.87 | F10 (1.00) | F10 | |
| SCHEMBL6712834 | 0.81 | F10 (0.69) | F10F2 | |
| SCHEMBL4479220 | 0.78 | F10 (1.00) | F10 | |
| SCHEMBL4477449 | 0.78 | F10 (0.81) | F10F2PLGPROCPRSS1 | |
| SCHEMBL4484131 | 0.76 | F10 (0.65) | F10 | |
| SCHEMBL4472147 | 0.76 | F10 (0.80) | F10 | |
| SCHEMBL14603100 | 0.75 | F10 (0.63) | F10F2PLGPROCPRSS1 | |
| SCHEMBL6714527 | 0.74 | F10 (0.75) | F10 | |
| SCHEMBL14603293 | 0.73 | F10 (0.77) | F10F2PLGPROCPRSS1 | |
| SCHEMBL14337591 | 0.73 | F10 (0.57) | F10F2PLGPROCPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, PRSS1 | F10 31/4885F2 21/4885PLG 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.